v3.26.3
Segment Information (Tables)
3 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The following table summarized significant segment expenses for the three months ended September 30, 2026 and 2025:

Psychedelic Medicine and Drug Therapies Segment
September 30,
2026
September 30,
2025
(in thousands)
Research and development expenses(1,123)(1,120)
General and administration expenses (excluding stock-based payment)(1,999)(2,982)
Stock-based payment(312)(2,626)